CSL to Acquire Majority Stake in Chinese Plasma Fractionator
Filed with ASX · · 15 pages · English
Watch CSL's latest callCSL (ASX:CSL) Q4 2026 Earnings Call · Replay · Aug 18Read the transcript of CSL (ASX:CSL) Q4 2026 Earnings Call• The transaction will complement CSL’s leadership position in China as a supplier of albumin and better serve patients with rare and serious diseases in this important high growth market CSL Limited (ASX:CSL; USOTC:CSLLY) announced today that it has agreed to acquire 80 per cent equity of plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (“Ruide”) from Hum
Earlier from CSL
- Half Year Results Release
- Half Year Results Analysts Presentation
- FY2017 Profit Upgrade
- AFSTYLA (rFVIII-Single Chain) European Commission Approval
- Positive Results from CSL112 Phase 2b Trial
Later from CSL
- FDA approves CSL Berhings HAEGARDA
- CSL Response to Patent Infringement Complaint
- CSL Completes Acquisition of Majority Stake in Ruide
- Appendix 4E, Directors Report and Financial Statements
- 2017 FY Results Announcement and Analysts Presentation
Follow CSL into a list and get an email when it puts out news.
Follow CSL